1989 Volume 80 Issue 1 Pages 74-81
During about 10 years from November, 1977 to March, 1987, two hundreds and fifty-five patients with bladder tumors were treated at the Department of Urology, Hamamatsu University School of Medicine and the affiliated hospitals.
There were 198 males and 57 females with the highest age incidence in the seventies. Histologically, 242, 11 and 2 tumors were of transitional cell, squamous cell and adenocarcinoma, respectively. Of the 242 transitional cell carcinomas, 7 were Tis; 43 Ta, 111 T1, 33 T2, 19 T3, 5 T4, 14 M+(with metastatic lesion), and 10 TX. As to grading, 6 was G0; 66 G1, 100 G2, 64 G3, and 6 GX. Staging was correlated with grading.
The 5-year survival rates (Kaplan-Meier's method) were 64% in patients with transitional cell carcinoma; 58% in those with squamous cell carcinoma. In patients with transitional cel carcinoma, the 5-year survival rates were 100% for G0, 73% for G1, 73% for G2 and 40% for G3. As to staging, the 5-year survival rates were 67%, 81%, 81%, 35%, 41%, 40% and 12% in patients with stage of Tis, Ta, T1, T2, T3, T4 and M+, respectively. As to the initial treatment, the 5-year survival rates after TUR (137 cases), partial cystectomy (4 cases) and total cystectomy (56 cases) were 81%, 36% and 61%, respectively.
The rate of intravesical recurrence after TUR was evaluated with the cumulative non-recurrence rate calculated by Kaplan-Meier's method. The 5-year non-recurrence rates after TUR (137 cases) were 58% overall; 63%, 59%, 58% and 80% in patients with G0, G1, G2 and G3, respectively. As to staging, the 5-year non-recurrence rates were 66%, 57% and 50% in patients with Ta, T1 and T2, respectively. The 5-year non-recurrence rates were 70% and 40% in single papillary and multiple papillary tumors, respectively. No patients with non-papillary tumors were found without recurrence 5 years after TUR. Intravesical recurrence after TUR was significantly more frequent in patients with multiple papillary tumor or non-papillary tumor than single papillary tumor. There was no significant difference with respect to grade, stage and prophylactic treatment in the non-recurrence rate.